New possibilities for type 2 diabetes mellitus therapy. Results of a pilot observation program of efficacy and safety of the drug «Galvus» (vildagliptin) therapy in Moscow and in the regions of the Russian Federation


如何引用文章

全文:

详细

The results of the study aimed to examination of efficacy and safety of drug Galvus (vildagliptin) in 1109 patients with type 2 diabetes mellitus (DM2) in the Russian clinical practice are presented. The findings showed that the use of the drug Galvus as monotherapy and in combination with metformin or sulfonylurea medications lead to significantly improvement of glycemic control in patients with DM2. This drug has no effect on body weight, can reduce body weight against the background of low-calorie diet and increasing physical activity. Vildagliptin is well tolerated, have no severe side effects and does not cause hypoglycemic state.

作者简介

M Pavlova

M Pavlova

参考

  1. Nathan DM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
  2. ABCD New simplified guidelines for Type 2 Diabetes treatment. Practical Diabetes Int 2009;26(5):191-94.
  3. Simplified flowchart for American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) 2009 glycemic control algorithm.
  4. Balas B, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92:1249-55.
  5. Galvus.Summary of Product Characteristics. Novartis Pharmaceuticals UK Ltd.: <http://www.medicines.org.uk>
  6. Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases apoptosis. ADA Annual Meeting 2005;572.
  7. Mari A, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94.
  8. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007;24:955-61.
  9. Dejager S, LeBeaut A, Couturier A, et al. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). ADA Annual Meeting 2006;120.
  10. Rosenstock J, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. A 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23.
  11. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomised trial. Diabetic Med 2008;25(4):435-41.
  12. Dejager S, et al. Efficacy of vildagliptin in drug-naïve patients with type 2 diabetes. Poster presented at ADA Annual Meeting, Washington, DC, 2006;791.
  13. Bosi E, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-95.
  14. Garber A, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylurea. Diabetes Obes Metab 2007.
  15. El-Ouaghlidi A, Rehring ER, Schweizer A, et al. The dipeptidyl peptidase IV inhibitor LAF 237 does not accentuate reactive hypoglycemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects. Diabetes 2003;52:118.
  16. Ferrannini E et al. 52-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab, 2009;(11):157-166.
  17. Fonseca V, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 0:1148-55.
  18. Dunning BE, Ligueros-Saylan M.. Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metformin-treated patients with type 2 diabetes. Presented at EASD 2006.
  19. Camisasca RP et al. Effects of vildagliptin on glucose control over 24 weeks in patients with Type 2 Diabetes inadequately controlled with metformin. Diabetes Care 2007;30(4):890-95.
  20. И.И. Дедов, М.В. Шестакова (ред.) Алгоритмы специализированной медицинской помощи больным сахарным диабетом. М., 2008.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2010
##common.cookie##